Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: A wisconsin oncology network study

Steven Attia, Anne M. Traynor, Kyungmann Kim, Joseph J. Merchant, Tien Hoang, Harish G. Ahuja, Peter A. Beatty, Richard M. Hansen, Gregory A. Masters, Kurt R. Oettel, Gary R. Shapiro, Martha M. Larson, Marilyn L. Larson, Joan H. Schiller

Research output: Contribution to journalArticle

Abstract

Introduction: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC. METHODS: Chemotherapy-naive patients ≥70-years-old with stage IIIB-IV NSCLC and a performance status (PS) ≤2 were eligible. Primary endpoints were the maximum tolerated dose (phase I) and time-to-progression (phase II) of oral exisulind with 25 mg/m/wk of intravenous vinorelbine on a 28-day cycle. Patients with clinical benefit after 6 cycles of this combination received exisulind alone. RESULTS: Fourteen phase I patients (median PS 1; median age 78 years) were enrolled. Dose-limiting toxicities included grade 3 constipation (one patient), grade 3 febrile neutropenia (one patient) and grade 3 diarrhea (one patient). The maximum tolerated dose of oral exisulind with 25 mg/m/wk of intravenous vinorelbine was 125 mg twice daily. Thirty phase II patients (median PS 1; median age 78 years) were enrolled. Grade ≥3 neutropenia occurred in 14/30 patients. Two patients experienced neutropenic fever. There were no complete responses, one partial response and 12 patients with stable disease as their best response. The objective response rate was 4.0% (95% CI: 0.1-20.4%). Phase II median time-to-progression was 4.7 months (95% CI: 3.1-9.3 months) and median OS was 9.6 months (95% CI: 6.6-19.1 months). CONCLUSIONS: This combination is safe, seems to have activity in the elderly with advanced NSCLC and a PS ≤2, and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1018-1025
Number of pages8
JournalJournal of Thoracic Oncology
Volume3
Issue number9
DOIs
StatePublished - Sep 2008

Keywords

  • Elderly
  • Exisulind
  • Non-small cell lung cancer
  • Phase I
  • Phase II
  • Sulindac sulfone
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: A wisconsin oncology network study'. Together they form a unique fingerprint.

  • Cite this

    Attia, S., Traynor, A. M., Kim, K., Merchant, J. J., Hoang, T., Ahuja, H. G., Beatty, P. A., Hansen, R. M., Masters, G. A., Oettel, K. R., Shapiro, G. R., Larson, M. M., Larson, M. L., & Schiller, J. H. (2008). Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: A wisconsin oncology network study. Journal of Thoracic Oncology, 3(9), 1018-1025. https://doi.org/10.1097/JTO.0b013e3181834fa1